An observational study in Diabetes Mellitus, Type 2, Obesity and Cortisol; Hypersecretion, sponsored by Istituto Auxologico Italiano. Recruiting at 5 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Istituto Auxologico Italiano · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy — 45 open to participants now, 61 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Italy.
Among the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, this one is the 21st largest by planned enrollment of the 99 observational ones that give a count, is one of 18 that started in 2022, is one of 99 observational ones, reaches primary completion later than 28 of the 60 other live ones, and was the 345th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →45 of the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Italy, United States, Argentina and 13 more countries
Ages 45+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Eli Lilly and Company · Sites in Italy, United States, Belgium and 8 more countries
Ages 10–17
AstraZeneca · Sites in Italy, United States, Argentina and 12 more countries
Ages 18+
Pfizer · Sites in Italy, United States, Brazil and 8 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
421 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 44 · Phase 3 157 · Phase 4 54
First in 1997; this study’s year is marked. 18 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,200 is above the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 320 across the 321 interventional studies, 500 across the 99 observational. Of the 317 that completed or were terminated, 132 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
227 of 421 have an industry lead sponsor. The 10 most frequent:
Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.
Istituto Auxologico Italiano has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
12 of the studies in Diabetes Mellitus, Type 2 with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07149610Marche Region Regional Health AgencyConnected Care for Type 2 Diabetes Self-Management | 2026-11-30 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07783893Marche Region Regional Health AgencyE-Health Literacy Intervention for Bangladeshi Migrants With Type 2 Diabetes in Italy | 2026-12 |
| NCT05759637Istituto Auxologico ItalianoType 2 Diabetes, Obesity and Cortisol Excess | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present observational cross-sectional study is aimed to assess: the hidden hypercortisolism (HidHyCo) prevalence in a sample of Type 2 diabetes (T2D) patients and the clinical characteristics more frequently associated with the HidHyCo presence and the HidHyCo prevalence in an adequate sample of obese patients without T2D and the clinical characteristics more frequently associated with the HidHyCo presence.
Mild and asymptomatic hypercortisolism has been described to be associated with increased prevalence of chronic complications of cortisol excess, such as osteoporosis, hypertension, type 2 diabetes (T2D) and obesity and with increased mortality. In patients with osteoporosis, hypertension, T2D or obesity, this form of hypercortisolism may remain occult (hidden hypercortisolism, HidHyCo), until its presence is suspected on the basis of particular characteristics of the underlying diseases. The HidHyCo prevalence in the general population is estimated to be 0.2-2%, but it has been suggested to be even higher (up to 10%) in some specific populations as for example in patients T2D. Data regarding the prevalence of HidHyCo in obese populations are limited, Therefore, the issue of which diabetic or obese patient has to be screened for HidHyCo has recently become a widely debated topic. Therefore, the aims of the present study protocol are to assess: i) the HidHyCo prevalence in a sample of T2D patients and the clinical characteristics more frequently associated with the HidHyCo presence; ii) the HidHyCo prevalence in an adequate sample of obese patients without T2D and the clinical characteristics more frequently associated with the HidHyCo presence.
All T2D and obese-without T2D patients between 18 and 75 years of age, consecutively referred to the out-patient clinics for Diabetes and Obesity of our center will be assessed for possible inclusion. At the enrolment in all patients anthropometric e biochemical variables will be recorded. At the enrolment we will evaluate cortisol levels after dexamethasone suppression test (F-1mgDST) in all T2D and obese-without T2D patients, who have been included in the study and who have given the informed consent to participate in the study. In all subjects with F-1mgDST >1.8 μg/dL, cortisol levels after two-day low dose (2 mg/day) dexamethasone suppression test (F-2mgx2dDST) will be performed. Patients with F-2mgx2dDST above >1.8 μg/dL will be considered affected with possible HidHyCo and will be studied following the available guidelines for the diagnosis of hypercortisolism.
All T2D and obese patients between 18 and 75 years of age, consecutively referred to the out-patient clinics for Diabetes and Obesity of our center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
patients with T2D and Obesity
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients with Type2 diabetes (T2D)
Diagnostic Test: 1mg DST
obese patients without Type 2 diabetes (T2D)
Diagnostic Test: 1mg DST
measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm
Hidden Hypercortisolism prevalence in a sample of T2D patients
prevalence of patients with F-1mgDST\>1.8 mcg/dl
Time frame: 24 months
Hidden Hypercortisolism prevalence in a sample of Obese patients
prevalence of patients with F-1mgDST\>1.8 mcg/dl
Time frame: 24 months
Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2025 → Dec 2026 and completion Dec 2025 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →